FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								. ()			1)		-							
Name and Address of Reporting Person* Menzel Garry E						2. Issuer Name and Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [TCRR]									S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O TCR2 THERAPEUTICS						3. Date of Earliest Transaction (Month/Day/Year) 06/01/2023									below)	er (give title Other (specify below) President and CEO				
100 BINNEY STREET						If Am	endm	ent, Date	of Original	Filed	I (Month/D		Individual or Joint/Group Filing (Check Applicable Line)							
(Street) CAMBRIDGE MA 02142					-										X Form filed by One Reporting Person Form filed by More than One Reporting Person					
				- -		101	ъГ 1/a\	T		ion los	1: 4			F 613011						
(City) (State) (Zip)				П	Che	eck this	s box to indi		rans	action was i	nade p	oursuan		act, instruction	n or written p	plan that	t is intended	l to		
		Tal	ole I - No	n-Der	ivative				quired,						y Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a 5)				Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								,	Code	v	Amount		(A) or (D)	Price	Reported Transactio (Instr. 3 ar	on(s)	(,, (nstr. 4)	
Common Stock				06/03	06/01/2023				D ⁽¹⁾		132,729		D	(2)	0		I		ee ootnote ⁽³⁾	
Common Stock 06/01				1/2023	2023			D ⁽¹⁾		132,73	132,730		(2)	0		I		ee ootnote ⁽⁴⁾		
Common Stock 06/01/2						023		D ⁽¹⁾		138,871		D	(2)	0		D				
			Table II						uired, D s, option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)		4. Transactio Code (Inst		on Derivative		6. Date Exercisabl Expiration Date (Month/Day/Year)		of Securities		ecurity	8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Expiration			Amount or Number of Shares	- Transa (Instr. 4		ction(s)					
Stock Option (Right to Buy)	\$0.74	06/01/2023			D ⁽¹⁾⁽⁵⁾			138,031	(5)		(5)	Com Sto		138,031	\$0.00	0		D		
Stock Option (Right to Buy)	\$5.88	06/01/2023			D ⁽¹⁾⁽⁵⁾			433,037	(5)		(5)	Com Sto		133,037	\$0.00	0		D		
Stock Option (Right to Buy)	\$5.21	06/01/2023			D ⁽¹⁾⁽⁵⁾			305,800	(5)		(5)	Com Sto		805,800	\$0.00	0		D		
Stock Option (Right to Buy)	\$0.97	06/01/2023			D ⁽¹⁾⁽⁵⁾			238,008	(5)		(5)	Com Sto		238,008	\$0.00	0		D		
Restricted Stock Unit	(6)(7)	06/01/2023			D ⁽¹⁾⁽⁶⁾ (7)			3,241	(6)(7)		(6)(7)	Com Sto		3,241	\$0.00	0		D		
Restricted Stock Unit	(6)(7)	06/01/2023			D ⁽¹⁾⁽⁶⁾ (7)			15,120	(6)(7)		(6)(7)	Com Sto		15,120	\$0.00	0		D		
Restricted Stock Unit	(6)(7)	06/01/2023			D ⁽¹⁾⁽⁶⁾ (7)			23,165	(6)(7)		(6)(7)	Com Sto		23,165	\$0.00	0		D		
Restricted Stock	(6)(7)	06/01/2023			D ⁽¹⁾⁽⁶⁾			39,681	(6)(7)		(6)(7)	Com	mon	39,681	\$0.00	0		D		

Explanation of Responses:

Stock

(7)

^{1.} This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics Inc. (the "Company"), Adaptimmune Therapeutics plc ("Parent") and CM Merger Sub, Inc., an indirect wholly-owned subsidiary of Parent ("Merger Sub"), as amended by that certain Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Company, Parent and Merger Sub (the "Merger Agreement"), pursuant to which Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time").

^{2.} At the Effective Time, each issued and outstanding share of common stock of the Company (each, a "Share") (excluding any Shares held in treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 1.5117 (the "Exchange Ratio") American Depositary Shares of Parent ("Parent ADS") representing six ordinary shares of Parent ("Parent Ordinary Shares").

- 3. Consists of 132,729 Shares held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The Reporting Person is the trustee of the Menzel Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Menzel Trust.
- 4. Consists of 132,730 Shares held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The Reporting Person's spouse is the trustee of the Henshall Trust, and as such the Reporting Person may be deemed to beneficially own such securities. The Reporting Person and members of his immediate family are the sole beneficiaries of the Henshall Trust.
- 5. Immediately prior to the Effective Time, each option to acquire Shares (each, a "Company Option") that was outstanding and unexercised, whether or not vested, was assumed and substituted for an option to purchase a number of Parent Ordinary Shares or Parent ADSs equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time multiplied by (ii) six times the Exchange Ratio, in the case of Parent Ordinary Shares, or the Exchange Ratio in the case of Parent ADSs.
- 6. Immediately prior to the Effective Time, each award of restricted stock unit with respect to Shares (each, a "Restricted Stock Unit"), other than Restricted Stock Units that immediately vest upon a change of on initial activities and the control of the Company, were assumed and substituted for a restricted stock unit. Style option to purchase Parent Ordinary Shares or Parent ADS, as applicable, equal to Pound Sterling 0.001 per Parent Ordinary Share or Pound Sterling 0.006 per Parent ADS (each, an "Adjusted Restricted Stock Unit Equivalent"), granted under one of Parent's incentive
- 7. The number of Parent Ordinary Shares or Parent ADSs subject to the Adjusted Restricted Stock Unit Equivalent shall be equal to the product of (i) the total number of Shares subject to such Restricted Stock Unit immediately prior to the Effective Time multiplied by (ii) the Ordinary Share Exchange Ratio (as defined in the Merger Agreement) or the Exchange Ratio, as applicable.

/s/ Margaret Siegel as Attorney-06/01/2023 in-Fact ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.